Insulin-producing cells grown in the lab could provide a possible cure for the age-long disease (diabetes).
Type 1 diabetes is an auto¬immune disease that wipes out insulin-producing pancreatic beta cells from the body and raises blood glucose to dangerously high levels. These high levels of Blood sugar level can be even fatal. Patients are being administered insulin and given other medications to maintain blood sugar level. To those who cannot maintain their blood sugar level, they are given beta-cell transplants but to tolerate beta cell transplants; patients have to take immunosuppressive drugs as well.
A report by a research group at Harvard University tells us that they used insulin-producing cells derived from human embryonic stem cells (ESCs) and induced pluripotent stem cells to lower blood glucose levels in mice. Nowadays, many laboratories are getting rapid progress in human stem cell technology to develop those cells that are functionally equivalent to beta-cells and the other pancreatic cell types. Other groups are developing novel biomaterials to encapsulate such cells and protect them against the immune system without the need for immunosuppressant.
Major pharmaceutical companies and life sciences venture capital firms have invested more than $100 million in each of the three most prominent biotechnological industries to bring such treatments into clinical use:
- Massachusetts–based companies Semma Therapeutics
- Sigilon Therapeutics, and ViaCyte of San Diego
Researchers of UC San Francisco have transformed human stem cells into mature insulin-producing cells for the first time, a breakthrough in the effort to develop a cure for type-1 (T1) Diabetes. Replacing these cells, which are lost in patients with T1 diabetes, has long been a dream of regenerative medicine, but until now scientists had not been able to find out how to produce cells in a lab dish that work as they do in healthy adults.
What is T1 diabetes?
T1 diabetes is an autoimmune disorder that destroys the insulin-producing beta cells of the pancreas, typically in childhood. Without insulin’s ability to regulate glucose levels in the blood, spikes in blood sugar can cause severe organ damage and eventually death. The condition can be managed by taking regular shots of insulin with meals. However, people with type 1 diabetes still often experience serious health consequences like kidney failure, heart disease and stroke. Patients facing life-threatening complications of their condition may be eligible for a pancreas transplant from a deceased donor, but these are rare, and they are supposed to wait a long time.
Researchers have just made a breakthrough that might one day make these technologies obsolete, by transforming human stem cells into functional insulin-producing cells (also known as beta cells) – at least in mice.
“We can now generate insulin-producing cells that look and act a lot like the pancreatic beta cells you and I have in our bodies,” explains one of the team, Matthias Hebrok from the University of California San Francisco (UCSF).
“This is a critical step towards our goal of creating cells that could be transplanted into patients with diabetes.”
Type-1 diabetes is characterized by a loss of insulin due to the immune system destroying cells in the pancreas – hence, type 1 diabetics need to introduce their insulin manually. Although this is a pretty good system, it’s not perfect.
Making insulin-producing cells from stem cells
Diabetes can be cured through an entire pancreas transplant or the transplantation of donor cells that produce insulin, but both of these options are limited because they rely on deceased donors. Scientists had already succeeded in turning stem cells into beta cells, but those cells remained stuck at an early stage in their maturity. That meant they weren’t responsive to blood glucose and weren’t able to secrete insulin in the right way.
Scientists at the University of California San Francisco made a breakthrough in the effort to cure diabetes mellitus type 1.
For the first time, researchers transformed human stem cells into mature insulin-producing cells, which could replace those lost in patients with the autoimmune. There is currently no known way to prevent type-1 (T1) diabetes, which destroys insulin production in the pancreas, limits glucose regulation, and results in high blood sugar levels. The condition can be managed with regular shots of insulin, but people with the disease often experience serious health complications like kidney failure, heart disease, and stroke.
“We can now generate insulin-producing cells that look and act a lot like the pancreatic beta cells you and I have in our bodies,” according to Matthias Hebrok, senior author of a study published last week in the journal Nature Cell Biology.
“This is a critical step toward our goal of creating cells that could be transplanted into patients with diabetes,” Hebrok, director of the UCSF Diabetes Center, said in a statement.
Islets of Langerhans are groupings of cells that contain healthy beta cells, among others. As beta cells develop, they have to separate physically from the pancreas to form these islets.
The team artificially separated the pancreatic stem cells and regrouped them into these islet clusters. When they did this, the cells matured rapidly and become responsive to blood sugar. In fact, the islet clusters developed in ways “never before seen” in a lab. After producing these mature cells, the team transplanted them into mice. Within days, the cells were producing insulin similar to the islets in the mice. While the study has been successful in mice, it still needs to go through more rigorous testing to see if it would work for humans as well. But the research is up-and-coming. “We can now generate insulin-producing cells that look and act a lot like the pancreatic beta cells you and I have in our bodies. This is a critical step towards our goal of creating cells that could be transplanted into patients with diabetes,” He said.
“We’re finally able to move forward on several different fronts that were previously closed to us,” he added. “The possibilities seem endless.”
Basic research keeps elucidating new aspects of beta cells; there seem to be several subtypes, so the gold standard for duplicating the cells is not entirely clear. Today, however, there is “a handful of groups in the world that can generate a cell that looks like a beta cell,” says Hebrok, who currently acts as scientific advisor to Semma and Sigilon, and has previously advised ViaCyte. “Certainly, companies have convinced themselves that what they have achieved is good enough to go into patients.”
The stem cell reprogramming methods that the three companies use to prompt cell differentiation create a mixture of islet cells. Beta cells sit in pancreatic islets of Langerhans alongside other types of endocrine cells. Alpha cells, for example, churn out glucagon, a hormone that stimulates the conversion of glycogen into glucose in the liver and raises blood sugar. Although the companies agree on the positive potential of islet cell mixtures, they take different approaches to developing and differentiating their cells. Semma, which was launched in 2014 to commercialize the Harvard group’s work and counts Novartis among its backers, describes its cells as fully mature, meaning that they are wholly differentiated into beta or other cells before transplantation. “Our cells are virtually indistinguishable from the ones you would isolate from donors,” says Semma chief executive officer BastianoSanna
To get around the donor problem, researchers, including the team at UCSF has been working on nudging stem cells into becoming fully-functional pancreatic beta cells for the last few years. Still, there have been some issues in getting them all the way there.
“The cells we and others were producing were getting stuck at an immature stage where they weren’t able to respond adequately to blood glucose and secrete insulin properly,” Hebrok said.
“It has been a major bottleneck for the field.”
“We’re finally able to move forward on a number of different fronts that were previously closed to us,” Hebrok added. “The possibilities seem endless.”
Regardless of starting cell type, the companies say they are ready to churn out their cells in large numbers. Semma, for example, can make more islet cells in a month than can be isolated from donors in a year in the United States, Sanna says, and the company’s “pristine” cells should perform better than donor islets, which are battered by the aggressive techniques required for their isolation.
As these products, some of which have already entered clinical trials, move toward commercialization, regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency have expressed concern about the plasticity of the reprogrammed cells. All three firms subject their cells to rigorous safety testing to ensure that they don’t turn tumorigenic. Before successful trials, companies won’t know the dose of beta cells required for a functional cure, or how long such “cures” will last before needing to be boosted. There’ll be commercial challenges, too: while the companies are investing heavily to develop suitable industrial processes, all acknowledge that no organization has yet manufactured cell therapies in commercial volumes.
Nevertheless, there’s growing confidence throughout the field that these problems will be solved, and soon. “We have the islet cells now,” says Alice Tomei, a biomedical engineer at the University of Miami who directs DRI’s Islet Immuno-engineering Laboratory.
“These stem cell companies are working hard to try to get FDA clearance on the cells.”
Protecting stem cell therapies from the immune system
Whatever the type of cell being used, another major challenge is delivering cells to the patient in a package that guards against immune attack while keeping cells fully functional. Companies are pursuing two main strategies:
- Microencapsulation, where cells are immobilized individually or as small clusters, in tiny blobs of a biocompatible gel.
- Macroencapsulation, in which greater numbers of cells are put into a much larger, implantable device.
ViaCyte, which recently partnered with Johnson & Johnson, launched its first clinical trial in 2014. The trial involved a micro-encapsulation approach that packaged up the company’s partially differentiated, ESC-derived cells into a flat device called the PEC-Encapsulation. About the size of a Band-Aid, the device is implanted under the skin, where the body forms blood vessels around it. “It has a semipermeable membrane that allows the free flow of oxygen, nutrients, and glucose,” says ViaCyte’s chief executive officer, Paul Laikind. “And even proteins like insulin and glucagon can move back and forth across that membrane, but cells cannot.”
The trial showed that the device was safe, well-tolerated, and protected from the adaptive immune system—and that some cells differentiated into working islet cells. But most cells didn’t engraft effectively because a “foreign body response,” a variant of wound healing, clogged the PEC-Encap’s membrane and prevented vascularization. ViaCyte stopped the trial and partnered with W. L. Gore & Associates, the maker of Gore-Tex, to engineer a new membrane. “With this new membrane,” says Laikind, “we’re not eliminating that foreign body response, but we’re overcoming it in such a way that allows vascularization to take place.” The company expects to resume the trial in the second half of this year, provided it receives the green light from the FDA.
Semma is also developing macro¬-encapsulation methods, including a very thin device that in prototype form is about the size of a silver dollar coin. The device is “deceptively simple, but it allows us to put [in] a fully curative dose of islets,” Sanna says.
Semma is also investigating microencapsulation alternatives. At the same time, the company is advancing toward clinical trials using established transplantation techniques to administer donated cadaver cells to high-risk patients who find it particularly difficult to control their blood glucose levels. These cells are infused via the portal vein into the liver, and patients take immunosuppressive drugs to prevent rejection.
Sigilon is working on its microencapsulation technology. Launched in 2016 on the back of work by the labs of Robert Langer and Daniel Anderson at MIT, the company has created 1.5-millimeter gel-based spheres that can hold between 5,000 and 30,000 cells (Nat Med, 22:306–11, 2016). Each sphere is like a balloon, with the outside chemically modified to provide immune-protection, says Sigilon chief executive officer Rogerio Vivaldi. “The inside of the balloon is full of a gel that creates almost a kind of a matrix net where the cells reside.”
In 2018, shortly after partnering with Eli Lilly, Sigilon and collaborators published research showing that islet cells that were encapsulated in gel spheres and transplanted into macaques remained functional for four months. The company has not disclosed a time frame for a type 1 diabetes trial “but we’re moving pretty quickly,” says chief scientific officer David Moller.
To conclude, all three firms hope to extend their work to treat some of the 400 million people worldwide with type 2 diabetes, many of them eventually benefit from insulin injections. The recent endorsements from big Pharmaceutical underline the real progress in beta-cell transplants, says Aaron Kowalski, a molecular geneticist and chief executive officer at JDRF, a foundation based in New York that has funded research at ViaCyte and academic labs whose work has been tapped by Semma and Sigilon. “These companies all realize that if they don’t do it, somebody else will. It’s hard to predict exactly when, but somebody is going to make this work.”
The online retailer launched its new line of products in July and will speak with physicians seeking new treatment products and protocols to alleviate patient suffering
MIAMI LAKES, Florida—Adimarket, LLC, an online marketplace for regenerative medicine practitioners and a subsidiary of the Global Stem Cells Group (GSCG), has taken to the road in a series of business trips with the intent of promoting the group’s new line of exosomes, a neonatal-derived stem cells product.
The exosomes products were launched in July 2019 in Buenos Aires, and during the weekend of August 23, Adimarket representatives were in Santiago de Chile to sponsor one of the regenerative medicine industry’s most prolific medical congresses, hosted by the Chilean Society of Aesthetic Surgery. During the event, Mr. Benito Novas, Chief Executive Officer of the Global Stem Cells Group, was on hand to officially launch the exosomes products with a lecture in the congress’ main room.
The Adimarket and GSCG teams will continue their series of business trips to introduce Adimarket’s line of exosomes products to physicians across the globe. Currently, two additional business trips are on the docket where representatives will attend two upcoming medical congresses.
On September 25, 2019 GSCG faculty members will attend the 4th International Congress of Aesthetic Gynecology in Veracruz, Mexico to be held at the Holiday Inn Hotel. One faculty member will speak to the audience about the newest exosomes products and their clinical applications.
The GSCG will also be hosting the International Cell Therapy Symposium on the University of Miami campus in Miami, Florida on October 24, 2019. The event is expected to draw a large attendance of physicians in the regenerative medicine field, and the GSCG has invited more than 10 scientists and practitioners with vast experience in regenerative medicine to host the congress’ educational sessions. At least five of the conference sessions will focus on how exosomes can help people suffering from degenerative diseases
“Adimarket, in conjunction with the Global Stem Cells Group, is pleased to be able to share its newest exosomes products with physicians across the globe practicing regenerative medicine,” said Benito Novas, CEO of the Global Stem Cells Group. “Our goal is to create groundbreaking products and treatment protocols that help physicians deliver innovative treatment options to their patients, helping to alleviate suffering caused by degenerative diseases.”
To learn more about Adimarket and its product offerings, visit https://www.adimarket.net/. To learn more about the Global Stem Cells Group and its efforts in the field of regenerative medicine, visit http://www.stemcellsgroup.com/.
The regenerative medicine symposium will be held on the University of Miami campus on October 24, 2019.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA) has announced its lineup of speakers for its upcoming Regenerative Medicine Symposium. The symposium will be held on the University of Miami campus in the Donna E. Shalala Student Center on October 24, 2019 and features an impressive lineup of global authorities in regenerative medicine.
ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. This year’s symposium hosted on the University of Miami campus will feature industry experts from seven countries, including Spain, Argentina, Bolivia, Colombia, Ecuador, Mexico, and the US. Some notable speakers include the following:
- Dra. Silvina Pastrana from Argentina, who serves as the Medical Director of the Stem Cells Center Buenos Aires. Dra. Pastrana will discuss her experiences in treating patients who suffer from osteoarthritis conditions.
- Dr. Pedro Sanchez hails from Colombia and is a highly regarded regenerative medicine and orthopedic specialist. He currently practices in Bogota where he offers stem cells treatments for people who suffer from orthopedic conditions.
- Dr. Miguel Guillermo Garbe of Spain serves as the president of the country’s Regenerative Medicine Association. He currently leads a seminal investigation on how to increase cardiological function in patients who have suffered from strokes.
- Dr. Roberto Blum from Ecuador has worked in the stem cells field for over 10 years and will share his industry experience with attendees.
- Dr. Victor Pereyra, an Argentinian neurosurgeon, will lecture on how ozone therapy and stem cells could help patients suffering from spinal injuries.
“The symposium will provide an informative day where physicians can learn from global leaders in the stem cells industry with the hopes of bringing new knowledge and treatment options back to their practices for their patients suffering from degenerative diseases.”
To learn more about the ISSCA and its Miami symposium, visithttp://www.stemcellsgroup.com/.
The group’s new permanent office in Cancun will help streamline the patient experience by providing holistic support throughout the treatment process.
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) today announced that it will be opening a permanent office in Cancun, Mexico. The decision to expand its corporate presence into Cancun was based on the rising demand for patients seeking stem cells treatments at the group’s facilities already established in Cancun. The GSCG maintains two regenerative medicine operations in Cancun, which include medical facilities and a stem cells laboratory.
GSCG’s Cancun facilities provide state-of-the art options for patients seeking stem cells treatments that are currently not available in the US. While these protocols and products are currently unavailable within the US’s borders due to regulations, the Cancun center has still adopted the FDA’s frameworks for safe and effective regenerative medicine products and therapies. Guided by these protocols, physicians at the center deliver safe and effective stem cells therapies and products that can help patients suffering from degenerative diseases recover more quickly than with traditional treatment protocols.
With the establishment of a permanent office presence in Cancun, the GSCG seeks to provide a seamless holistic experience for patients seeking treatment at its facilities. With its office located near its medical center and laboratory, the GSCG team can more closely monitor the treatment process from the time the patient arrives at the Cancun airport to the time their treatment is complete and they return to the US.
“The Global Stem Cells Group is pleased to establish a permanent presence in Cancun with the opening of this new office location,” said Benito Novas, CEO of the Global Stem Cells Group. “By expanding our presence, we will be able to open up additional treatment opportunities for physicians in the US who may be limited by FDA regulations in ensuring their patients receive the critical stem cells therapies they need. US patients looking for relief from regenerative diseases are welcome at our Cancun center and will appreciate our state-of-the art facilities and top-notch care.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
The new Stem Cells Lab is set to break ground in 2020, providing affordable regenerative medicine products to Latin America and the US
MIAMI LAKES, Florida—The Global Stem Cells Group today announced that it will be expanding its research and production efforts with a new lab in Mexico. The lab is the group’s first facility of its kind and will produce neonatal tissue-derived products such as exosomes, cord blood derived stem cells, and amniotic fluid derived products. Groundbreaking is slated for January 2020.
The Global Stem Cells Group is a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. To further the group’s mission, the new lab will fill a much-needed research and production niche in the regenerative medicine field and will be especially beneficial to physicians practicing in Latin America and the United States.
The lab will strictly adhere to all Good Manufacturing Practice (GMP) standards. Although the lab will be located in Mexico, all products will be procured and processed according to the standards and regulations set forth by the American Association of Tissue Banks (AATB) and the United States Food and Drug Administration (FDA). All tissue will come from local donors, with the lab strictly adhering to donor ethics and the FDA’s approved serological screening policies.
In addition to producing neonatal tissue derived products, the lab will also facilitate clinical trials to explore the safety and efficacy of new regenerative medicine products before they launch. The lab will also serve as a teaching and learning center for doctors and scientists across the globe looking to learn more about stem cells protocols.
“The Global Stem Cells Group is committed to facilitating stem cell research and medicine across the globe,” said Benito Novas, CEO of the Global Stem Cells Group. “Our new lab in Mexico will allow us to make good on this mission by delivering more affordable neonatal tissues derived products to doctors across Latin America and the US. As a result, more patients will find relief from debilitating degenerative diseases.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
The group’s new platelet-rich plasma (PRP) offering meets international standards for compliance, safety, and efficacy
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group, today announced the availability of a new product that is a viable treatment option in a host of regenerative medicine sectors. With its new platelet-rich plasma (PRP) product, Adimarket will provide physicians with an exciting treatment protocol that can deliver relief to patients needing critical aesthetic, wound, and orthopedic care.
PRP is a super biological product of sorts, composed of a higher concentration of platelets than what is usually found in blood — 6-10 times more, on average. Adimarket’s PRP kit is the first of its kind in the stem cells and regenerative medicine industry, seeking to deliver higher platelet counts in an affordable and easy-to-use system. The revolutionary system is designed to shorten total processing time and reduce human error as it maximizes platelet concentration numbers. Adimarket’s offering has the capability of producing both leukocyte-rich and leukocyte-poor PRP and works in a variety of centrifuge systems.
PRP has been gaining interest and traction in the world of stem cell therapies and regenerative medicine. For clinicians working in the aesthetics, wound care, and orthopedic sectors, PRP has proven be a promising treatment option in offering relief to their patients.
In developing its PRP product, Adimarket researchers and scientists adhered to the highest international standards, making the product a viable option for physicians across the globe. With the launch of this new product, Adimarket is looking to expand its reach into new markets across the Middle East and Europe.
“Adimarket and its products have been met with great enthusiasm from physicians in the US and Latin America,” said Benito Novas, CEO of the Global Stem Cells Group. “With the launch of this new PRP product, our goal is to continue to serve our partners in those markets while expanding our presence into Europe and the Middle East. Our ultimate goal is to help more physicians across the globe deliver critical stem cell treatments to their patients, with the goal of alleviating unnecessary suffering.”
The keynote will highlight trends in social media marketing for physicians working in aesthetics
MIAMI LAKES, Florida—Benito Novas, CEO of Aesthetica Marketing Group (AMG), has been selected to serve as the keynote speaker at the upcoming Congreso del la Sociedad Chilena de Medicina y Estética. AMG, which is sponsoring the Chilean congress, is an American company focused on providing doctors working in the aesthetics medical industry practical solutions for their marketing challenges. The congress will be held on August 22-24, 2019 at the Hotel InterContinental Santiago in Santiago, Chile.
The annual event is the group’s main event, attracting physicians in the aesthetics medical industry across Chile and beyond. Novas’ keynote lecture will highlight current trends and best practices in social media and how physicians working in the aesthetics industry can better leverage social media in increasing the success of their practices.
During the congress, AMG will also launch two new courses focused on the aesthetics market, Pellet Therapy Certification and an IV/Chelation course.
The Pellet Therapy Certification course will provide practitioners with comprehensive clinical knowledge of this therapy option—one that is gaining rapid traction and recognition globally. Facilitators will present scientific reviews, case studies, and procedural training during the workshop. Attendees will be provided an in-depth introduction to pellet therapy, supported by reviews of clinical evidence on the need for customized dosing, in addition to assessing pellet dosing protocols for male and female patients. Pellet sterility, equipment, and what to look for in a compounding pharmacy will also be discussed.
AMG’s IV/Chelation course has been redesigned and now includes the most recent practices and protocols in intravenous nutritional therapies, in addition to chelation therapy in regard to its uses in lead toxicity and other heavy metals. Lecturers will not only cover the fundamentals of IV therapy and expand on the use of vitamins, minerals, amino acids, and other unique parenteral compounds but also review various aspects of integrating IV therapy into practice, as well as implementation strategies. Faculty presenters additionally will discuss potential application of the therapy in cancer treatment protocols, thus giving attendees the unique opportunity to learn about the most cutting-edge uses of IV therapy as a treatment method. At the conclusion of the course, clinicians will have a thorough understanding of how to perform IV therapy in both theory and practice.
To learn more about the upcoming Congreso del la Sociedad Chilena de Medicina y Estética or to register, visit https://sochimce.cl/congreso/. To learn more about Aesthetica Marketing Group, visit https://esteticamarketing.com/.
Adimarket, LLC Launches New Product for Physicians Seeking Regenerative Medicine and Stem Cell Centers
The comprehensive guide, “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center” is available for purchase on Adimarket’s online store.
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group, has launched a new product for physicians interested in starting regenerative medicine and stem cell treatment centers. The guide, entitled “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center” provides physicians with valuable information to guide them through the process of proposing and setting up new centers in the industry.
The comprehensive guide provides physicians with a one-stop place to find information critical to setting up a treatment center and includes information about training, equipment installation, cellular product storage procedures, supply inventories, laboratory startup, and more. The guide covers both scientific and administrative training concepts to help enable physicians to start their own centers at the lowest cost possible.
By following the guide, clinic officials will be able to launch a center with a wide range of cell lineages and products available, as well as have at its disposal the industry’s leading patient treatment protocols and standard operating procedures used by the Global Stem Cells Group’s global clinical network.
“For physicians looking to add regenerative medicine protocols to their current practices, Adimarket’s guide is a must-have resource,” said Benito Novas, CEO of the Global Stem Cells Group. “Our hope is that our guide will give more physicians the knowledge, tools, and confidence necessary to offer regenerative medicine and stem cell treatments to their patients to help alleviate suffering.”
To learn more about Adimarket and to purchase the “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center,” visit https://www.adimarket.net/. To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
The Global Stem Cells CEO will give two additional lectures on marketing and future outlooks for the stem cells industry as well as lead a magistral class for attendees
MIAMI LAKES, Florida—Benito Novas has been invited as a keynote speaker at an upcoming medical congress hosted by the Mexican Board of Aesthetic Gynecology. The group’s fourth congress, the 4to Congreso Internacional de Ginecología Lasar y Funcional, will be held on September 25-28, 2019 at the Holiday Inn hotel in Boca del Rio in Veracruz, Mexico.
Novas, is the Vice President of Public Relations of the International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. In addition to his keynote speech, Novas will also lecture on two additional topics during the congress as well as lead a magistral class for conference attendees.
Benito Novas is a highly sought-after speaker in the world of stem cell advancements, having served as a successful business owner in the industry with his holding the Global Stem Cells Group. Thanks to Novas’ and his team’s efforts, access to regenerative medicine has expanded exponentially across the globe. Additionally, Novas is a well-regarded marketing professional who has created a successful marketing model for private medical organizations to expand and grow their industry recognition.
Congress attendees will have the opportunity to hear Novas’ talks on the current and future state of stem cells as well as the importance of digital marketing in the medical field. In his lecture on current and future outlooks for stem cells advancement, Novas will share information about current stem cells clinical trials and growing expectations in the industry as well as how FDA policies can influence markets not only in the US but also beyond.
In his lecture on digital marketing, Novas will address why doctors must utilize digital marketing strategies to grow a successful practice. He will look at current trends in how people meet each other and network in today’s increasingly digital world and how social medial plays a role in today’s networking. He will additionally provide strategic tips to attendees on how to capitalize on social media trends to grow practice influence. Some of the tools Novas will discuss include Google Ads and Facebook Ads, as well as what type of content to post to generate engagement with prospective customers and clients.
Novas will also conduct a magistral class following the congress for professionals interested in learning more about digital marketing. During the course, Novas will discuss how practitioners can implement the latest marketing techniques into their practices, including how to create a powerhouse digital marketing team by using platforms such as Fiverr, Upwork, and others.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.
ISSCA will partner with SIISDET at the October 2019 event, which will share valuable information with physicians regarding recent breakthroughs in regenerative medicine
MIAMI LAKES, Florida—The International Society for Stem Cells Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will co-host a symposium in October 2019 with the Sociedad Internacional en Investigación, Salud, Desarrollo Empresarial (SIISDET). The event will be held at the University of Miami on October 22-24, 2019 in the West Ballroom of the Shalala Student Complex.
The Miami symposium will feature educational sessions and product information and demonstrations aimed at doctors looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to share the latest information on the newest compounds in the allogeneic stem cells market, including exosomes, amniotic fluid compounds, and cord blood products.
Allogeneic compounds have gained growing popularity in regenerative medicine due to their increased safety and treatment efficacy. With this in mind, ISSCA representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their practices.
“We are pleased to be able to partner with SIISDET to be able to offer this exciting symposium at the University of Miami,” said Benito Novas, CEO of ISSCA. “We are continually seeking ways to bring the latest advances in regenerative medicine to physicians across the globe. Our Miami symposium will play a critical role in accomplishing this by helping physicians expand their knowledge bases and explore new treatment options in regenerative medicine.”
In addition to educational sessions, the Miami symposium will provide networking and social opportunities for those in attendance. Events on the agenda include an optional boat trip around Miami on the Miami River and a Columbian Day celebration offering live music and Colombian cuisine to symposium attendees.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.